Glaukos/$GKOS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Ticker

$GKOS

Primary listing

NYSE

Industry

Health Care Equipment & Supplies

Employees

995

ISIN

US3773221029

Glaukos Metrics

BasicAdvanced
$5.8B
-
-$2.27
0.88
-

What the Analysts think about Glaukos

Analyst ratings (Buy, Hold, Sell) for Glaukos stock.

Bulls say / Bears say

Glaukos reported record net sales of $96.7 million in Q3 2024, a 24% increase from the previous year, indicating strong market demand for its products. (nasdaq.com)
The company's glaucoma segment experienced a 30% rise in sales during the same period, showcasing robust growth in a key therapeutic area. (nasdaq.com)
Glaukos raised its 2024 net sales guidance, reflecting confidence in its strategic plans and the advancement of innovative therapies for eye diseases. (nasdaq.com)
Despite record sales, Glaukos reported a net loss of $21.4 million in Q3 2024, highlighting ongoing profitability challenges. (nasdaq.com)
The company's debt-to-equity ratio stood at 0.83 as of December 2023, indicating a relatively high level of debt compared to equity, which could pose financial risks. (gurufocus.com)
Glaukos's net income decreased by 25% year-over-year, and its operating income declined by 16% in the same period, suggesting potential operational inefficiencies. (fullratio.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Glaukos Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Glaukos Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GKOS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs